KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Bio-Rad Laboratories (BIO) Long-Term Debt Issuances (2010 - 2022)

Bio-Rad Laboratories (BIO) reported Long-Term Debt Issuances of -$20000.0 for Q4 2022, down 100.0% on a QoQ basis from $1.2 billion in Q1 2022.

Bio-Rad Laboratories (BIO) has 2 years of Long-Term Debt Issuances data on file, last reported at -$20000.0 in Q4 2022.

  • Quarterly Long-Term Debt Issuances changed N/A year-over-year to -$20000.0 in Q4 2022, while the trailing twelve-month figure through Sep 2023 was -$20000.0 (down 100.0% YoY) and the FY2022 annual result came in at $1.2 billion, changed N/A from the prior year.
  • Long-Term Debt Issuances declined to -$20000.0 in Q4 2022 per BIO's latest filing, from $1.2 billion in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $1.2 billion in Q1 2022 and bottomed at -$20000.0 in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 19.86 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 11.71 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 1.15 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Bio-Rad Laboratories 8.23 Bn 6.66 Bn 309.40 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 -20,000.00
Dec 31, 2022 -20,000.00
Mar 31, 2022 1.19 Bn
Mar 31, 2022 1.19 Bn
Dec 31, 2010 422.63 Mn
Dec 31, 2010 422.63 Mn